RPSA/Laminin Receptor Antikörper (AA 101-200)
Kurzübersicht für RPSA/Laminin Receptor Antikörper (AA 101-200) (ABIN729583)
Target
Alle RPSA/Laminin Receptor (RPSA) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
- 
    - 
                                            Bindungsspezifität
- AA 101-200
- 
                                            Kreuzreaktivität
- Human, Maus, Ratte
- 
                                            Homologie
- Dog
- 
                                            Aufreinigung
- Purified by Protein A.
- 
                                            Immunogen
- KLH conjugated synthetic peptide derived from human LAMR1
- 
                                            Isotyp
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            Applikationshinweise
- 
                        WB 1:300-5000
 ELISA 1:500-1000
 FCM 1:20-100
 IHC-P 1:200-400
 IHC-F 1:100-500
 IF(IHC-P) 1:50-200
 IF(IHC-F) 1:50-200
 IF(ICC) 1:50-200
- 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Format
- Liquid
- 
                                            Konzentration
- 1 μg/μL
- 
                                            Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- 
                                            Konservierungsmittel
- ProClin
- 
                                            Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 
                                            Lagerung
- 4 °C,-20 °C
- 
                                            Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- 
                                            Haltbarkeit
- 12 months
 
- 
                                            
- 
    - 
                                            : "A dock derived compound against laminin receptor (37 LR) exhibits anti-cancer properties in a prostate cancer cell line model."    in: Oncotarget, Vol. 9, Issue 5, pp. 5958-5978, (2018)         (PubMed).        
 
 
- 
                                            : "A dock derived compound against laminin receptor (37 LR) exhibits anti-cancer properties in a prostate cancer cell line model."    in: Oncotarget, Vol. 9, Issue 5, pp. 5958-5978, (2018)         (PubMed).        
- 
    - RPSA/Laminin Receptor (RPSA) (Ribosomal Protein SA (RPSA))
- 
                                            Andere Bezeichnung
- LAMR1
- 
                                            Hintergrund
- 
                        Synonyms: 40S ribosomal protein SA, 37 kDa laminin receptor precursor, 37LRP, 37/67 kDa laminin receptor, LRP/LR, 67 kDa laminin receptor, 67LR, Colon carcinoma laminin-binding protein, Laminin receptor 1, LamR, Laminin-binding protein precursor p40, LBP/p40, Multidrug resistance-associated protein MGr1-Ag, NEM/1CHD4, RPSA, LAMBR, LAMR1 Background: Required for the assembly and/or stability of the 40S ribosomal subunit. Required for the processing of the 20S rRNA-precursor to mature 18S rRNA in a late step of the maturation of 40S ribosomal subunits. Also functions as a cell surface receptor for laminin. Plays a role in cell adhesion to the basement membrane and in the consequent activation of signaling transduction pathways. May play a role in cell fate determination and tissue morphogenesis. Acts as a PPP1R16B-dependent substrate of PPP1CA. Also acts as a receptor for several other ligands, including the pathogenic prion protein, viruses, and bacteria. 
- 
                                            Gen-ID
- 3921
- 
                                            UniProt
- P08865
- 
                                            Pathways
- Ribonucleoprotein Complex Subunit Organization, Ribosome Assembly
 Target
- 
                    
 
                                     
                                     
                                    